Stage IV Liver Cancer

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (05-27-2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Nexavar Superior to Sutent in Liver Cancer (06-23-2011)

Nexavar® (sorafenib) provides superior overall survival to Sutent® (sunitinib) in the treatment of hepatocellular (liver) cancer. These results were presented at the 2011 annual American Society of Clinical Oncology (ASCO) meeting. Hepatocellular carcinoma... Continue Reading

Cabozantinib Shows Promise against Bone Metastases (05-31-2011)

The investigational drug cabozantinib is showing promise against several types of advanced cancer, and may also reduce or eliminate bone metastases (cancer that has spread to the bone) in some patients. These results will be presented at the 2011 annual... Continue Reading

FDA Grants Orphan Drug Status to Investigational Liver Cancer Drug (05-2-2011)

PV-10—an investigational liver cancer drug—has been designated an orphan drug by the US Food and Drug Administration (FDA). The orphan drug designation is intended to encourage the development of drugs for rare diseases by providing incentives for... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (11-16-2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Combination Chemotherapy Improves Survival with Biliary Tract Cancer (05-17-2010)

According to the results of a Phase III clinical trial, treatment of locally advanced or metastatic biliary tract cancer with a combination of Gemzar® (gemcitabine) and cisplatin results in better survival and a lower risk of cancer progression than... Continue Reading

Sutent® Not Effective for Advanced Liver Cancer (07-10-2009)

In a Phase II clinical trial, patients with inoperable, advanced hepatocellular (liver) cancer did not benefit from treatment with the targeted therapy Sutent® (sunitinib). The results of this study were published in Lancet Oncology. Hepatocellular carcinoma... Continue Reading

Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma (03-8-2009)

Avastin® plus Tarceva® Shows Promise in Advanced Hepatocellular Carcinoma According to the results of a Phase II clinical trial, the combination of two targeted therapies-Avastin® (bevacizumab) and Tarceva® (erlotinib)-has anticancer activity in patients... Continue Reading

Nexavar® Effective for Hepatocellular Carcinoma in Asians (03-8-2009)

Nexavar® Effective for Hepatocellular Carcinoma in Asians Researchers from 23 medical centers in Asia have reported that Nexavar® (sorafenib) is effective in patients with advanced hepatocellular carcinoma (liver cancer). The results of this study were... Continue Reading